论文部分内容阅读
用ＭＴＴ法测定了重组人促红细胞生成素（ｒｈｕ－ＥＰＯ）对Ｋ５６２／Ａ０２多药耐药细胞系细胞和Ｋ５６２药物敏感细胞增殖的影响。研究发现，Ｋ５６２／Ａ０２与浓度为００７８、０１５６Ｕ／ｍＬ的促红素分别孵育时，其增殖活力比无ｒｈｕ－ＥＰＯ因子组低（Ｐ＜００１）；而Ｋ５６２与上述同样浓度的ｒｈｕ－ＥＰＯ孵育条件下，其增殖活力与无因子组比较差异无显著性意义（Ｐ＞０２０）。以上结果表明，ｒｈｕ－ＥＰＯ可能有抑制Ｋ５６２／Ａ０２细胞增殖的作用，而对Ｋ５６２细胞增殖无影响，提示ｒｈｕ－ＥＰＯ可能对多药耐药白血病的治疗有一些效果
The effect of recombinant human erythropoietin (rhu-EPO) on the proliferation of K562 / A02 multi-drug resistant cell lines and K562 drug sensitive cells was determined by MTT assay. The results showed that when K562 / A02 was incubated with erythropoietin at concentrations of 0078 and 0156 U / mL respectively, its proliferation activity was lower than that without rhu-EPO (P <001), while K562 was the same as above Concentration of rhu-EPO incubation conditions, the proliferation of vitality and no factor group was no significant difference (P> 0 20). The above results show that rhu-EPO may inhibit the proliferation of K562 / A02 cells, but have no effect on the proliferation of K562 cells, suggesting that rhu-EPO may have some effects on the treatment of multi-drug resistant leukemia